JP2013535210A - パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 - Google Patents
パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 Download PDFInfo
- Publication number
- JP2013535210A JP2013535210A JP2013522292A JP2013522292A JP2013535210A JP 2013535210 A JP2013535210 A JP 2013535210A JP 2013522292 A JP2013522292 A JP 2013522292A JP 2013522292 A JP2013522292 A JP 2013522292A JP 2013535210 A JP2013535210 A JP 2013535210A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- seq
- sequence
- protelomerase
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004414 DNA Proteins 0.000 title claims abstract description 353
- 108091081548 Palindromic sequence Proteins 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 36
- 230000003321 amplification Effects 0.000 claims abstract description 80
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 80
- 102000053602 DNA Human genes 0.000 claims description 350
- 238000000034 method Methods 0.000 claims description 116
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 80
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 80
- 230000027455 binding Effects 0.000 claims description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 34
- 238000006073 displacement reaction Methods 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000010076 replication Effects 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 10
- 238000005096 rolling process Methods 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108700028149 Bacteriophage N15 protelomerase Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 5
- 239000000047 product Substances 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 46
- 102000004190 Enzymes Human genes 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 32
- 150000007523 nucleic acids Chemical group 0.000 description 31
- 230000004544 DNA amplification Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 19
- 241001515965 unidentified phage Species 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 15
- 238000000137 annealing Methods 0.000 description 15
- 238000012545 processing Methods 0.000 description 15
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 108010041986 DNA Vaccines Proteins 0.000 description 11
- 229940021995 DNA vaccine Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000004925 denaturation Methods 0.000 description 11
- 230000036425 denaturation Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000009609 Pyrophosphatases Human genes 0.000 description 10
- 108010009413 Pyrophosphatases Proteins 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000001103 potassium chloride Substances 0.000 description 10
- 235000011164 potassium chloride Nutrition 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000705957 Yersinia phage PY54 Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000589969 Borreliella burgdorferi Species 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 241001478599 Escherichia phage N15 Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000011535 reaction buffer Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000006820 DNA synthesis Effects 0.000 description 6
- 241000658605 Halomonas virus HAP1 Species 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 241000701844 Bacillus virus phi29 Species 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 5
- 108010017826 DNA Polymerase I Proteins 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 241000036036 Vibrio virus VP882 Species 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 235000013919 monopotassium glutamate Nutrition 0.000 description 5
- 108091028732 Concatemer Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 4
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 4
- 241001376756 Klebsiella phage phiKO2 Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- -1 CA19.9 Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
- 101000587455 Homo sapiens Single-stranded DNA-binding protein, mitochondrial Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000588749 Klebsiella oxytoca Species 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 102100029719 Single-stranded DNA-binding protein, mitochondrial Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 101150057615 Syn gene Proteins 0.000 description 2
- 101150104425 T4 gene Proteins 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013578 denaturing buffer Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000001915 proofreading effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- JNMCQUJGQWZYMW-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O JNMCQUJGQWZYMW-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
- LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710172562 Cobra venom factor Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010043461 Deep Vent DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 241000206596 Halomonas Species 0.000 description 1
- 241001299659 Halomonas aquamarina Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 description 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical class [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 102100022497 Mucin-3A Human genes 0.000 description 1
- 102100022693 Mucin-4 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100326371 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bst-1 gene Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607284 Vibrio sp. Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6846—Common amplification features
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1013153.0A GB201013153D0 (en) | 2010-08-04 | 2010-08-04 | Primer for production of closed linear DNA |
| GB1013153.0 | 2010-08-04 | ||
| PCT/GB2011/001175 WO2012017210A1 (en) | 2010-08-04 | 2011-08-04 | Production of closed linear dna using a palindromic sequence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202277A Division JP6689726B2 (ja) | 2010-08-04 | 2016-10-14 | パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013535210A true JP2013535210A (ja) | 2013-09-12 |
| JP2013535210A5 JP2013535210A5 (enExample) | 2014-09-18 |
Family
ID=42931209
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013522292A Pending JP2013535210A (ja) | 2010-08-04 | 2011-08-04 | パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 |
| JP2016202277A Active JP6689726B2 (ja) | 2010-08-04 | 2016-10-14 | パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202277A Active JP6689726B2 (ja) | 2010-08-04 | 2016-10-14 | パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9499847B2 (enExample) |
| EP (1) | EP2601312B1 (enExample) |
| JP (2) | JP2013535210A (enExample) |
| CN (1) | CN103080337B (enExample) |
| GB (1) | GB201013153D0 (enExample) |
| WO (1) | WO2012017210A1 (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| KR20170045349A (ko) * | 2014-09-05 | 2017-04-26 | 터치라이트 아이피 리미티드 | Dna의 합성 |
| WO2018015995A1 (ja) * | 2016-07-19 | 2018-01-25 | 株式会社バイオダイナミクス研究所 | 長鎖一本鎖ｄｎａを調製する方法 |
| JP2023511991A (ja) * | 2020-01-31 | 2023-03-23 | ティリス セラピューティクス，エセ．エレ． | 閉じた直鎖ｄｎａを作製するためのプロセス |
| JP2023533174A (ja) * | 2020-06-12 | 2023-08-02 | ユニバーシティ オブ ロチェスター | ＡＣＥ－ｔＲＮＡのコード化及び発現 |
| WO2024058155A1 (ja) * | 2022-09-12 | 2024-03-21 | 株式会社カネカ | 二本鎖環状ｄｎａベクター、直鎖状共有結合閉鎖ｄｎａの作製方法、並びにプロテロメラーゼ及びエンドヌクレアーゼを含む融合ポリペプチド |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0901593D0 (en) * | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
| EP2692870A1 (en) * | 2012-08-03 | 2014-02-05 | Alacris Theranostics GmbH | Method for nucleic acid amplification |
| AU2014233145A1 (en) | 2013-03-15 | 2015-09-17 | Theranos Ip Company, Llc | Nucleic acid amplification |
| JP2016521120A (ja) | 2013-03-15 | 2016-07-21 | セラノス， インコーポレイテッド | 核酸増幅 |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US9290800B2 (en) | 2013-03-15 | 2016-03-22 | Pacific Biosciences Of California, Inc. | Targeted rolling circle amplification |
| CA2903874C (en) | 2013-03-15 | 2024-02-20 | Theranos, Inc. | Nucleic acid amplification |
| WO2015035260A1 (en) | 2013-09-06 | 2015-03-12 | Theranos, Inc. | Systems and methods for detecting infectious diseases |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| CA2948728A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| WO2015148863A2 (en) | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3126495A1 (en) | 2014-04-02 | 2017-02-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating primary open angle glaucoma |
| GB201502645D0 (en) | 2015-02-17 | 2015-04-01 | Touchlight Genetics Ltd | Method |
| EP3286571B1 (en) | 2015-04-24 | 2021-08-18 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| WO2017165862A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| CA3032822A1 (en) | 2016-08-02 | 2018-02-08 | Editas Medicine, Inc. | Compositions and methods for treating cep290 associated disease |
| US11505821B2 (en) * | 2016-08-16 | 2022-11-22 | Touchlight IP Limited | Closed linear DNA production |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| US10350307B2 (en) * | 2017-09-18 | 2019-07-16 | General Electric Company | In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides |
| ES2998052T3 (en) | 2017-10-24 | 2025-02-18 | Editas Medicine Inc | Systems and methods for treating hyper-igm syndrome |
| US20200263206A1 (en) | 2017-11-07 | 2020-08-20 | Editas Medicine, Inc. | Targeted integration systems and methods for the treatment of hemoglobinopathies |
| CA3085338A1 (en) | 2017-12-11 | 2019-06-20 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019118806A1 (en) * | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
| KR102907245B1 (ko) | 2018-03-14 | 2026-01-05 | 에디타스 메디신, 인코포레이티드 | 혈색소병증 치료를 위한 시스템 및 방법 |
| CN108531496B (zh) * | 2018-04-04 | 2020-11-06 | 江南大学 | 一种提高外源基因mRNA数量的DNA及其应用 |
| GB201805683D0 (en) | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| CA3104113A1 (en) | 2018-06-22 | 2019-12-26 | Asklepios Biopharmaceutical, Inc. | Vectors for gene delivery that persist within cells |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| MA56520A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Construction de l'interleukine 12 recombinante et ses utilisations |
| WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| WO2020255008A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| KR20220041080A (ko) | 2019-06-18 | 2022-03-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합 |
| AU2020296372A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody |
| MA56534A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) |
| AU2020295807A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
| EP3792367A1 (en) | 2019-09-11 | 2021-03-17 | Universität Bielefeld | Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest |
| GB2606844B (en) | 2019-09-18 | 2025-08-06 | Aldevron Llc | Synthetic DNA vectors and methods of use |
| GB201915163D0 (en) | 2019-10-18 | 2019-12-04 | Univ Southampton | Cancer vaccine |
| GB202007428D0 (en) | 2020-05-19 | 2020-07-01 | Fabricnano Ltd | Polynucleotide synthesis |
| CN112111544B (zh) * | 2020-09-23 | 2022-04-01 | 复旦大学附属肿瘤医院 | 提高单链dna连接效率的方法 |
| CN116848253A (zh) * | 2021-01-22 | 2023-10-03 | 南京金斯瑞生物科技有限公司 | 用于生产目的dna序列的方法和克隆载体 |
| EP4060049B1 (en) * | 2021-03-18 | 2023-08-23 | Genomill Health Oy | Methods for accurate parallel quantification of nucleic acids in dilute or non-purified samples |
| GB202108176D0 (en) | 2021-06-08 | 2021-07-21 | Touchlight Ip Ltd | Vector |
| CA3222751A1 (en) | 2021-06-08 | 2022-12-15 | Touchlight IP Limited | Lentiviral vector |
| WO2022272297A1 (en) | 2021-06-25 | 2022-12-29 | Oxford Biomedica Solutions Llc | Adeno-associated virus packaging systems |
| WO2023285976A1 (en) | 2021-07-13 | 2023-01-19 | Stonehaven Incubate AG | Composition and uses thereof |
| GB202114105D0 (en) | 2021-10-01 | 2021-11-17 | Fabricnano Ltd | Nucleotide synthesis |
| EP4419677A4 (en) | 2021-10-18 | 2025-09-24 | Flagship Pioneering Innovations Vii Llc | DNA COMPOSITIONS AND RELATED METHODS |
| US20230323395A1 (en) | 2021-12-15 | 2023-10-12 | Homology Medicines, Inc. | Methods and compositions for the production of adeno-associated virus |
| CA3243028A1 (en) | 2021-12-20 | 2025-04-07 | Zoetis Services Llc | USE OF INTERFERON AS AN ADJUVANT IN VACCINES |
| CN118414349A (zh) | 2021-12-20 | 2024-07-30 | 硕腾服务有限责任公司 | 用于在细胞膜上表达抗原的组合物和方法 |
| EP4453008A1 (en) | 2021-12-20 | 2024-10-30 | Zoetis Services LLC | Compositions and methods for prevention of piscine myocarditis |
| CN114561372B (zh) * | 2022-04-27 | 2022-07-26 | 南京巨匠生物科技有限公司 | Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 |
| EP4293101A1 (en) | 2022-06-14 | 2023-12-20 | Asklepios Biopharmaceutical, Inc. | Reactor with temperature control and method of using the same |
| CN119698477A (zh) * | 2022-08-10 | 2025-03-25 | 镇江蓬勃生物科技有限公司 | 线性闭合dna的制备方法及该方法所用质粒 |
| WO2024039652A1 (en) | 2022-08-16 | 2024-02-22 | Aldevron, L.L.C. | Cell-free method of producing synthetic circular nucleic acid |
| AU2023342975A1 (en) | 2022-09-12 | 2025-03-20 | Zoetis Services Llc | Method of administration of aquaculture vaccines |
| CN117778498A (zh) * | 2022-09-26 | 2024-03-29 | 深圳瑞吉生物科技有限公司 | 一种无细胞制备mRNA转录模板的方法 |
| AU2023352042A1 (en) | 2022-09-29 | 2025-04-10 | Ceva Hampton Limited | Vaccine construct and uses thereof |
| WO2024121354A1 (en) * | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| DK202370610A1 (en) | 2022-12-13 | 2024-07-12 | Zoetis Services Llc | Methods of vaccine administration to salmonids |
| WO2024197081A1 (en) | 2023-03-20 | 2024-09-26 | Hc Bioscience, Inc. | Minimally-sized dna threads for trna therapy |
| CN116606834A (zh) * | 2023-04-10 | 2023-08-18 | 天津中合基因科技有限公司 | 多种具有切割连接活性的原端酶及其应用 |
| WO2024256842A1 (en) | 2023-06-16 | 2024-12-19 | Touchlight IP Limited | Therapeutic transfection |
| CN121816413A (zh) | 2023-08-18 | 2026-04-07 | 镇江蓬勃生物科技有限公司 | 纯化核酸分子的方法 |
| US11981936B1 (en) | 2023-09-29 | 2024-05-14 | New England Biolabs, Inc. | TelA variants, compositions, and methods |
| GB202319998D0 (en) | 2023-12-22 | 2024-02-07 | Touchlight Ip Ltd | duplexing method |
| WO2025202929A1 (en) * | 2024-03-29 | 2025-10-02 | Pfizer Inc. | Methods for producing nucleic acids |
| WO2025250742A1 (en) * | 2024-05-30 | 2025-12-04 | Aclarity Genomics, Inc. | Amplification of macromolecules |
| WO2025264964A1 (en) | 2024-06-20 | 2025-12-26 | Zoetis Services Llc | Vaccines against tenacibaculum finnmarkense |
| EP4729632A1 (en) | 2024-10-18 | 2026-04-22 | AskBio Inc. | Method of synthesizing dna |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10234399A (ja) * | 1997-02-28 | 1998-09-08 | Shinkinrui Kinou Kaihatsu Kenkyusho:Kk | ピシウム属菌検出用の核酸配列 |
| US20030170693A1 (en) * | 2001-12-21 | 2003-09-11 | George Chaconas | Assay for identifying modulators of Borrelia telomere resolvase |
| JP2008522628A (ja) * | 2004-12-11 | 2008-07-03 | サイトジェニックス， インコーポレイテッド | 高品質核酸のセルフリー生合成及びその使用 |
| WO2010026099A1 (en) * | 2008-09-02 | 2010-03-11 | General Electric Company | Dna mini-circles and uses thereof |
| WO2010086626A1 (en) * | 2009-01-30 | 2010-08-05 | Touchlight Genetics Limited | Production of closed linear dna |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JPH03236781A (ja) * | 1990-02-13 | 1991-10-22 | Takara Shuzo Co Ltd | ランダムプライマーキット及びその使用方法 |
| JPH06500014A (ja) | 1990-07-25 | 1994-01-06 | シンジーン，インコーポレイテッド | 多数の核酸相補体を生成させる環状伸長法 |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| US6953676B1 (en) | 1992-05-01 | 2005-10-11 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
| WO1994003624A1 (en) * | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
| US5714320A (en) | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| DE69429038T2 (de) | 1993-07-28 | 2002-03-21 | Pe Corporation (Ny), Norwalk | Vorrichtung und Verfahren zur Nukleinsäurevervielfältigung |
| WO1995011923A1 (en) * | 1993-10-29 | 1995-05-04 | Dana-Farber Cancer Institute, Inc. | A novel tumor marker and novel method of isolating same |
| FR2732971B1 (fr) | 1995-04-13 | 1997-07-04 | Genset Sa | Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US6143495A (en) | 1995-11-21 | 2000-11-07 | Yale University | Unimolecular segment amplification and sequencing |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| US6054274A (en) | 1997-11-12 | 2000-04-25 | Hewlett-Packard Company | Method of amplifying the signal of target nucleic acid sequence analyte |
| ATE400358T1 (de) | 1997-12-24 | 2008-07-15 | Cepheid | Vorrichtung und verfahren zur lyse |
| CA2317896C (en) | 1998-01-09 | 2004-08-10 | University Of Utah Research Foundation | Method for in vitro amplification of circular dna |
| DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
| CA2342838A1 (en) | 1998-09-15 | 2000-03-23 | Yale University | Molecular cloning using rolling circle amplification |
| EP1203078B1 (de) | 1999-07-08 | 2005-05-04 | Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze |
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| GB0018120D0 (en) | 2000-07-24 | 2000-09-13 | Fermentas Ab | Nuclease |
| JP2002051784A (ja) * | 2000-08-09 | 2002-02-19 | Toyobo Co Ltd | 核酸の増幅方法及び標識核酸の調製方法 |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| US20030077611A1 (en) | 2001-10-24 | 2003-04-24 | Sention | Methods and systems for dynamic gene expression profiling |
| US7081339B2 (en) | 2002-04-12 | 2006-07-25 | Primera Biosystems, Inc. | Methods for variation detection |
| CA2492203A1 (en) | 2002-07-12 | 2004-01-22 | Affymetrix, Inc. | Synthetic tag genes |
| ES2270120T3 (es) | 2002-09-23 | 2007-04-01 | Mologen Ag | Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. |
| US7955795B2 (en) | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
| WO2004065582A2 (en) | 2003-01-15 | 2004-08-05 | Dana-Farber Cancer Institute, Inc. | Amplification of dna in a hairpin structure, and applications |
| EP1594987B1 (en) | 2003-02-21 | 2009-05-27 | GeneForm Technologies Limited | Nucleic acid sequencing methods, kits and reagents |
| EP1706502A4 (en) | 2003-11-26 | 2007-05-23 | Eppendorf Ag | METHODS AND COMPOSITIONS FOR IN VITRO AMPLIFICATION OF EXTRACHROMOSOMIC NUCLEIC ACID |
| JP3972106B2 (ja) * | 2004-03-03 | 2007-09-05 | 大学共同利用機関法人情報・システム研究機構 | ゲノムライブラリー作製方法、および同方法により作製されたゲノムライブラリー |
| CN101103122A (zh) * | 2004-12-11 | 2008-01-09 | 西托吉尼克斯公司 | 高质量核酸的无细胞生物合成及其用途 |
| WO2006108423A2 (en) | 2005-04-12 | 2006-10-19 | In Situ Rcp A/S Under Founding | Methods for production of oligonucleotides |
| ATE474937T1 (de) | 2005-04-29 | 2010-08-15 | Synthetic Genomics Inc | Amplifikation und klonierung einzelner dna- moleküle mittels rolling-circle-amplifikation |
| EP1974037B1 (en) | 2006-01-12 | 2012-03-14 | Lucigen Corporation | Linear vectors, host cells and cloning methods |
| EP3527671A1 (en) | 2006-10-06 | 2019-08-21 | Applied DNA Sciences Inc. | System for a continuous rapid thermal cycle system |
| US20080118917A1 (en) * | 2006-11-21 | 2008-05-22 | Applera Corporation | Isothermal SNP Detection Method |
| JP5182949B2 (ja) * | 2009-03-31 | 2013-04-17 | 浜名部品工業株式会社 | ヨークの製造方法及び製造装置 |
| US9114399B2 (en) | 2010-08-31 | 2015-08-25 | Canon U.S. Life Sciences, Inc. | System and method for serial processing of multiple nucleic acid assays |
| EP2692870A1 (en) | 2012-08-03 | 2014-02-05 | Alacris Theranostics GmbH | Method for nucleic acid amplification |
| KR102014989B1 (ko) | 2013-04-15 | 2019-08-27 | 삼성전자주식회사 | 폴리뉴클레오티드 및 그의 용도 |
-
2010
- 2010-08-04 GB GBGB1013153.0A patent/GB201013153D0/en not_active Ceased
-
2011
- 2011-08-04 WO PCT/GB2011/001175 patent/WO2012017210A1/en not_active Ceased
- 2011-08-04 US US13/814,106 patent/US9499847B2/en active Active
- 2011-08-04 JP JP2013522292A patent/JP2013535210A/ja active Pending
- 2011-08-04 EP EP11746284.6A patent/EP2601312B1/en active Active
- 2011-08-04 CN CN201180038378.5A patent/CN103080337B/zh active Active
-
2016
- 2016-10-14 JP JP2016202277A patent/JP6689726B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10234399A (ja) * | 1997-02-28 | 1998-09-08 | Shinkinrui Kinou Kaihatsu Kenkyusho:Kk | ピシウム属菌検出用の核酸配列 |
| US20030170693A1 (en) * | 2001-12-21 | 2003-09-11 | George Chaconas | Assay for identifying modulators of Borrelia telomere resolvase |
| JP2008522628A (ja) * | 2004-12-11 | 2008-07-03 | サイトジェニックス， インコーポレイテッド | 高品質核酸のセルフリー生合成及びその使用 |
| WO2010026099A1 (en) * | 2008-09-02 | 2010-03-11 | General Electric Company | Dna mini-circles and uses thereof |
| WO2010086626A1 (en) * | 2009-01-30 | 2010-08-05 | Touchlight Genetics Limited | Production of closed linear dna |
Non-Patent Citations (2)
| Title |
|---|
| JPN6015029950; ＨＥＩＮＲＩＣＨ， Ｊ． ｅｔ ａｌ．: Ｊ． Ｍｏｌ． Ｍｅｄ． Ｖｏｌ．８０, 2002, ｐｐ．６４８-６５４ * |
| JPN6015029951; ＭＯＲＥＮＯ， Ｓ． ｅｔ ａｌ．: Ｖａｃｃｉｎｅ Ｖｏｌ．２２, 2004, ｐｐ．１７０９-１７１６ * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102497228B1 (ko) * | 2014-09-05 | 2023-02-07 | 터치라이트 아이피 리미티드 | Dna의 합성 |
| KR20170045349A (ko) * | 2014-09-05 | 2017-04-26 | 터치라이트 아이피 리미티드 | Dna의 합성 |
| JP2017525384A (ja) * | 2014-09-05 | 2017-09-07 | タッチライト・アイピー・リミテッド | Ｄｎａの合成 |
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2018015995A1 (ja) * | 2016-07-19 | 2018-01-25 | 株式会社バイオダイナミクス研究所 | 長鎖一本鎖ｄｎａを調製する方法 |
| JP7004651B2 (ja) | 2016-07-19 | 2022-02-04 | 株式会社バイオダイナミクス研究所 | 長鎖一本鎖ｄｎａを調製する方法 |
| JPWO2018015995A1 (ja) * | 2016-07-19 | 2019-05-09 | 株式会社バイオダイナミクス研究所 | 長鎖一本鎖ｄｎａを調製する方法 |
| JP2023511991A (ja) * | 2020-01-31 | 2023-03-23 | ティリス セラピューティクス，エセ．エレ． | 閉じた直鎖ｄｎａを作製するためのプロセス |
| JP7771066B2 (ja) | 2020-01-31 | 2025-11-17 | ティリス セラピューティクス，エセ．エレ． | 閉じた直鎖ｄｎａを作製するためのプロセス |
| JP2023533174A (ja) * | 2020-06-12 | 2023-08-02 | ユニバーシティ オブ ロチェスター | ＡＣＥ－ｔＲＮＡのコード化及び発現 |
| WO2024058155A1 (ja) * | 2022-09-12 | 2024-03-21 | 株式会社カネカ | 二本鎖環状ｄｎａベクター、直鎖状共有結合閉鎖ｄｎａの作製方法、並びにプロテロメラーゼ及びエンドヌクレアーゼを含む融合ポリペプチド |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012017210A1 (en) | 2012-02-09 |
| EP2601312B1 (en) | 2017-04-12 |
| CN103080337A (zh) | 2013-05-01 |
| GB201013153D0 (en) | 2010-09-22 |
| US9499847B2 (en) | 2016-11-22 |
| JP6689726B2 (ja) | 2020-04-28 |
| EP2601312A1 (en) | 2013-06-12 |
| CN103080337B (zh) | 2016-08-17 |
| JP2017035102A (ja) | 2017-02-16 |
| US20130216562A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6689726B2 (ja) | パリンドローム配列を用いた閉鎖型直鎖状ｄｎａの生成 | |
| JP6454243B2 (ja) | 閉鎖型直鎖状ｄｎａの製造 | |
| US12509718B2 (en) | Method of DNA synthesis | |
| KR20240004618A (ko) | Ruvc 도메인을 갖는 효소 | |
| HK1215045A1 (zh) | 用於制备闭合线状dna的体外无细胞方法的试剂盒 | |
| HK1159693B (en) | Production of closed linear dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140729 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150728 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160614 |